Click for best price
Neurological Disorder Drugs Market Size, Share 2024
| Market size in 2023 |
US$ 1850 million
|
Forecast Market size by 2030 |
US$ 3400.7 million
|
| Growth Rate |
CAGR of 9.2% |
Number of Pages |
95 Pages |
This research report provides a comprehensive analysis of the Neurological Disorder Drugs market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Neurological Disorder Drugs market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Neurological Disorder Drugs, challenges faced by the industry, and potential opportunities for market players.
The global Neurological Disorder Drugs market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Neurological Disorder Drugs market presents opportunities for various stakeholders, including Hospital, Clinic. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Neurological Disorder Drugs market. Additionally, the growing consumer demand present avenues for market expansion.
The global Neurological Disorder Drugs market was valued at US$ 1850 million in 2023 and is projected to reach US$ 3400.7 million by 2030, at a CAGR of 9.2% during the forecast period.
Staggering increase in brain altering disorders such as Alzheimer?s, epilepsy, Parkinson?s, cerebrovascular, and sclerosis are promoting the pharmaceutical firms to tap into the significantly growing neurological disorder drugs market. This will potentially supplement the market growth in the coming years. Rise of several innovative drugs to manage these diseases will swell up the investments in the market. Increasing number of clinical trials are another reason boosting the market. Rise in geriatric population along with patients with strokes, migraines, and headaches leading to cerebrovascular diseases are likely to augment the growth of the market.
Key Features:
The research report on the Neurological Disorder Drugs market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Neurological Disorder Drugs market.
Market Overview: The report provides a comprehensive overview of the Neurological Disorder Drugs market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Antipsychotic, Hypnotic & Sedative), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Neurological Disorder Drugs market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Neurological Disorder Drugs market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Neurological Disorder Drugs market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Neurological Disorder Drugs market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Neurological Disorder Drugs market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Neurological Disorder Drugs market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Neurological Disorder Drugs, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Neurological Disorder Drugs market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Neurological Disorder Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
- Antipsychotic
- Hypnotic & Sedative
- Analgesics
- Anticoagulants
- Others
- Market segment by Application
- Hospital
- Clinic
Global Neurological Disorder Drugs Market Segment Percentages, By Region and Country, 2023 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Major players covered
- Novartis
- GlaxoSmithKline
- Merck & Co.
- Bayer
- AstraZeneca
- Boehringer Ingelheim
- Teva Pharmaceutical
Outline of Major Chapters:
Chapter 1: Introduces the definition of Neurological Disorder Drugs, market overview.
Chapter 2: Global Neurological Disorder Drugs market size in revenue.
Chapter 3: Detailed analysis of Neurological Disorder Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neurological Disorder Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Neurological Disorder Drugs Market, Global Outlook and Forecast 2024-2030 |
| Market size in 2023 |
US$ 1850 million
|
| Forecast Market size by 2030 |
US$ 3400.7 million
|
| Growth Rate |
CAGR of 9.2% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
95 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Neurological Disorder Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Neurological Disorder Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Neurological Disorder Drugs Overall Market Size
2.1 Global Neurological Disorder Drugs Market Size: 2023 VS 2030
2.2 Global Neurological Disorder Drugs Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Neurological Disorder Drugs Players in Global Market
3.2 Top Global Neurological Disorder Drugs Companies Ranked by Revenue
3.3 Global Neurological Disorder Drugs Revenue by Companies
3.4 Top 3 and Top 5 Neurological Disorder Drugs Companies in Global Market, by Revenue in 2023
3.5 Global Companies Neurological Disorder Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Neurological Disorder Drugs Players in Global Market
3.6.1 List of Global Tier 1 Neurological Disorder Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Neurological Disorder Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Neurological Disorder Drugs Market Size Markets, 2023 & 2030
4.1.2 Antipsychotic
4.1.3 Hypnotic & Sedative
4.1.4 Analgesics
4.1.5 Anticoagulants
4.1.6 Others
4.2 By Type - Global Neurological Disorder Drugs Revenue & Forecasts
4.2.1 By Type - Global Neurological Disorder Drugs Revenue, 2019-2024
4.2.2 By Type - Global Neurological Disorder Drugs Revenue, 2025-2030
4.2.3 By Type - Global Neurological Disorder Drugs Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Neurological Disorder Drugs Market Size, 2023 & 2030
5.1.2 Hospital
5.1.3 Clinic
5.2 By Application - Global Neurological Disorder Drugs Revenue & Forecasts
5.2.1 By Application - Global Neurological Disorder Drugs Revenue, 2019-2024
5.2.2 By Application - Global Neurological Disorder Drugs Revenue, 2025-2030
5.2.3 By Application - Global Neurological Disorder Drugs Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Neurological Disorder Drugs Market Size, 2023 & 2030
6.2 By Region - Global Neurological Disorder Drugs Revenue & Forecasts
6.2.1 By Region - Global Neurological Disorder Drugs Revenue, 2019-2024
6.2.2 By Region - Global Neurological Disorder Drugs Revenue, 2025-2030
6.2.3 By Region - Global Neurological Disorder Drugs Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Neurological Disorder Drugs Revenue, 2019-2030
6.3.2 US Neurological Disorder Drugs Market Size, 2019-2030
6.3.3 Canada Neurological Disorder Drugs Market Size, 2019-2030
6.3.4 Mexico Neurological Disorder Drugs Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Neurological Disorder Drugs Revenue, 2019-2030
6.4.2 Germany Neurological Disorder Drugs Market Size, 2019-2030
6.4.3 France Neurological Disorder Drugs Market Size, 2019-2030
6.4.4 U.K. Neurological Disorder Drugs Market Size, 2019-2030
6.4.5 Italy Neurological Disorder Drugs Market Size, 2019-2030
6.4.6 Russia Neurological Disorder Drugs Market Size, 2019-2030
6.4.7 Nordic Countries Neurological Disorder Drugs Market Size, 2019-2030
6.4.8 Benelux Neurological Disorder Drugs Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Neurological Disorder Drugs Revenue, 2019-2030
6.5.2 China Neurological Disorder Drugs Market Size, 2019-2030
6.5.3 Japan Neurological Disorder Drugs Market Size, 2019-2030
6.5.4 South Korea Neurological Disorder Drugs Market Size, 2019-2030
6.5.5 Southeast Asia Neurological Disorder Drugs Market Size, 2019-2030
6.5.6 India Neurological Disorder Drugs Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Neurological Disorder Drugs Revenue, 2019-2030
6.6.2 Brazil Neurological Disorder Drugs Market Size, 2019-2030
6.6.3 Argentina Neurological Disorder Drugs Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Neurological Disorder Drugs Revenue, 2019-2030
6.7.2 Turkey Neurological Disorder Drugs Market Size, 2019-2030
6.7.3 Israel Neurological Disorder Drugs Market Size, 2019-2030
6.7.4 Saudi Arabia Neurological Disorder Drugs Market Size, 2019-2030
6.7.5 UAE Neurological Disorder Drugs Market Size, 2019-2030
7 Neurological Disorder Drugs Companies Profiles
7.1 Novartis
7.1.1 Novartis Company Summary
7.1.2 Novartis Business Overview
7.1.3 Novartis Neurological Disorder Drugs Major Product Offerings
7.1.4 Novartis Neurological Disorder Drugs Revenue in Global Market (2019-2024)
7.1.5 Novartis Key News & Latest Developments
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Company Summary
7.2.2 GlaxoSmithKline Business Overview
7.2.3 GlaxoSmithKline Neurological Disorder Drugs Major Product Offerings
7.2.4 GlaxoSmithKline Neurological Disorder Drugs Revenue in Global Market (2019-2024)
7.2.5 GlaxoSmithKline Key News & Latest Developments
7.3 Merck & Co.
7.3.1 Merck & Co. Company Summary
7.3.2 Merck & Co. Business Overview
7.3.3 Merck & Co. Neurological Disorder Drugs Major Product Offerings
7.3.4 Merck & Co. Neurological Disorder Drugs Revenue in Global Market (2019-2024)
7.3.5 Merck & Co. Key News & Latest Developments
7.4 Bayer
7.4.1 Bayer Company Summary
7.4.2 Bayer Business Overview
7.4.3 Bayer Neurological Disorder Drugs Major Product Offerings
7.4.4 Bayer Neurological Disorder Drugs Revenue in Global Market (2019-2024)
7.4.5 Bayer Key News & Latest Developments
7.5 AstraZeneca
7.5.1 AstraZeneca Company Summary
7.5.2 AstraZeneca Business Overview
7.5.3 AstraZeneca Neurological Disorder Drugs Major Product Offerings
7.5.4 AstraZeneca Neurological Disorder Drugs Revenue in Global Market (2019-2024)
7.5.5 AstraZeneca Key News & Latest Developments
7.6 Boehringer Ingelheim
7.6.1 Boehringer Ingelheim Company Summary
7.6.2 Boehringer Ingelheim Business Overview
7.6.3 Boehringer Ingelheim Neurological Disorder Drugs Major Product Offerings
7.6.4 Boehringer Ingelheim Neurological Disorder Drugs Revenue in Global Market (2019-2024)
7.6.5 Boehringer Ingelheim Key News & Latest Developments
7.7 Teva Pharmaceutical
7.7.1 Teva Pharmaceutical Company Summary
7.7.2 Teva Pharmaceutical Business Overview
7.7.3 Teva Pharmaceutical Neurological Disorder Drugs Major Product Offerings
7.7.4 Teva Pharmaceutical Neurological Disorder Drugs Revenue in Global Market (2019-2024)
7.7.5 Teva Pharmaceutical Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Neurological Disorder Drugs Market Opportunities & Trends in Global Market
Table 2. Neurological Disorder Drugs Market Drivers in Global Market
Table 3. Neurological Disorder Drugs Market Restraints in Global Market
Table 4. Key Players of Neurological Disorder Drugs in Global Market
Table 5. Top Neurological Disorder Drugs Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Neurological Disorder Drugs Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Neurological Disorder Drugs Revenue Share by Companies, 2019-2024
Table 8. Global Companies Neurological Disorder Drugs Product Type
Table 9. List of Global Tier 1 Neurological Disorder Drugs Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Neurological Disorder Drugs Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Neurological Disorder Drugs Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Neurological Disorder Drugs Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Neurological Disorder Drugs Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Neurological Disorder Drugs Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Neurological Disorder Drugs Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Neurological Disorder Drugs Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Neurological Disorder Drugs Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Neurological Disorder Drugs Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Neurological Disorder Drugs Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Neurological Disorder Drugs Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Neurological Disorder Drugs Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Neurological Disorder Drugs Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Neurological Disorder Drugs Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Neurological Disorder Drugs Revenue, (US$, Mn), 2025-2030
Table 30. Novartis Company Summary
Table 31. Novartis Neurological Disorder Drugs Product Offerings
Table 32. Novartis Neurological Disorder Drugs Revenue (US$, Mn) & (2019-2024)
Table 33. Novartis Key News & Latest Developments
Table 34. GlaxoSmithKline Company Summary
Table 35. GlaxoSmithKline Neurological Disorder Drugs Product Offerings
Table 36. GlaxoSmithKline Neurological Disorder Drugs Revenue (US$, Mn) & (2019-2024)
Table 37. GlaxoSmithKline Key News & Latest Developments
Table 38. Merck & Co. Company Summary
Table 39. Merck & Co. Neurological Disorder Drugs Product Offerings
Table 40. Merck & Co. Neurological Disorder Drugs Revenue (US$, Mn) & (2019-2024)
Table 41. Merck & Co. Key News & Latest Developments
Table 42. Bayer Company Summary
Table 43. Bayer Neurological Disorder Drugs Product Offerings
Table 44. Bayer Neurological Disorder Drugs Revenue (US$, Mn) & (2019-2024)
Table 45. Bayer Key News & Latest Developments
Table 46. AstraZeneca Company Summary
Table 47. AstraZeneca Neurological Disorder Drugs Product Offerings
Table 48. AstraZeneca Neurological Disorder Drugs Revenue (US$, Mn) & (2019-2024)
Table 49. AstraZeneca Key News & Latest Developments
Table 50. Boehringer Ingelheim Company Summary
Table 51. Boehringer Ingelheim Neurological Disorder Drugs Product Offerings
Table 52. Boehringer Ingelheim Neurological Disorder Drugs Revenue (US$, Mn) & (2019-2024)
Table 53. Boehringer Ingelheim Key News & Latest Developments
Table 54. Teva Pharmaceutical Company Summary
Table 55. Teva Pharmaceutical Neurological Disorder Drugs Product Offerings
Table 56. Teva Pharmaceutical Neurological Disorder Drugs Revenue (US$, Mn) & (2019-2024)
Table 57. Teva Pharmaceutical Key News & Latest Developments
List of Figures
Figure 1. Neurological Disorder Drugs Segment by Type in 2023
Figure 2. Neurological Disorder Drugs Segment by Application in 2023
Figure 3. Global Neurological Disorder Drugs Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Neurological Disorder Drugs Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Neurological Disorder Drugs Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Neurological Disorder Drugs Revenue in 2023
Figure 8. By Type - Global Neurological Disorder Drugs Revenue Market Share, 2019-2030
Figure 9. By Application - Global Neurological Disorder Drugs Revenue Market Share, 2019-2030
Figure 10. By Type - Global Neurological Disorder Drugs Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Neurological Disorder Drugs Revenue Market Share, 2019-2030
Figure 12. By Application - Global Neurological Disorder Drugs Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Neurological Disorder Drugs Revenue Market Share, 2019-2030
Figure 14. By Region - Global Neurological Disorder Drugs Revenue Market Share, 2019-2030
Figure 15. By Country - North America Neurological Disorder Drugs Revenue Market Share, 2019-2030
Figure 16. US Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Neurological Disorder Drugs Revenue Market Share, 2019-2030
Figure 20. Germany Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2030
Figure 21. France Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Neurological Disorder Drugs Revenue Market Share, 2019-2030
Figure 28. China Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2030
Figure 32. India Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Neurological Disorder Drugs Revenue Market Share, 2019-2030
Figure 34. Brazil Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Neurological Disorder Drugs Revenue Market Share, 2019-2030
Figure 37. Turkey Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Neurological Disorder Drugs Revenue, (US$, Mn), 2019-2030
Figure 41. Novartis Neurological Disorder Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. GlaxoSmithKline Neurological Disorder Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. Merck & Co. Neurological Disorder Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Bayer Neurological Disorder Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. AstraZeneca Neurological Disorder Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Boehringer Ingelheim Neurological Disorder Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. Teva Pharmaceutical Neurological Disorder Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
